Table 2.
Clinical events in 37 patients with CTD-ILD receiving rituximab.
| Variable | Total n = 37 |
RA n = 19 |
SS n = 14 |
IM n = 4 |
p Value |
|---|---|---|---|---|---|
| Infections, n (%) | 29 (78.4) | 15 (78.9) | 11 (78.6) | 3 (75.0) | 0.985 |
| Respiratory infection, n (%) | 26 (70.3) | 13 (68.4) | 10 (71.4) | 3 (75.0) | 0.959 |
| Other infections, n (%) | 10 (27.0) | 5 (26.3) | 4 (28.6) | 1(25.0) | 0.980 |
| Herpes simplex labialis, n (%) | 2 (5.4) | 1 (5.2) | 0 (0.0) | 1 (25.0) | 0.333 |
| Cutaneous involvement, n (%) | 5 (13.5) | 2 (10.5) | 3 (21.4) | 0 (0.0) | 0.401 |
| Urinary tract infection, n (%) | 5 (13.5) | 3 (15.7) | 1 (7.1) | 1 (25.0) | 0.560 |
| Hospitalization, n (%) | 16 (43.2) | 10 (52.6) | 5 (35.7) | 1 (25.0) | 0.461 |
| Reasons for hospitalization | 0.360 | ||||
| Progression of ILD, n (%) | 10 (27.0) | 7 (36.8) | 3 (21.4) | 0 (0.0) | |
| Respiratory infection, n (%) | 14 (37.8) | 7 (36.8) | 6 (42.8) | 1 (25.0) | |
| Mortality, n (%) | 7 (18.9) | 6 (31.6) | 1 (7.1) | 0 (0.0) | 0.123 |
Abbreviations: CTD: connective tissue disease; ILD: interstitial lung disease; RA: rheumatoid arthritis; MI: inflammatory myopathy; SS: systemic sclerosis. Statistical tests used: Pearson chi-squared (χ2), ANOVA, and Kruskal–Wallis.